Ashwini Shewade

426 total citations
25 papers, 266 citations indexed

About

Ashwini Shewade is a scholar working on Genetics, Rheumatology and Pathology and Forensic Medicine. According to data from OpenAlex, Ashwini Shewade has authored 25 papers receiving a total of 266 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 9 papers in Rheumatology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Ashwini Shewade's work include Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (8 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). Ashwini Shewade is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (8 papers) and Rheumatoid Arthritis Research and Therapies (8 papers). Ashwini Shewade collaborates with scholars based in United States, Switzerland and Canada. Ashwini Shewade's co-authors include Joel M. Kremer, Ani John, George Reed, Jeffrey D. Greenberg, Jill Garrison, John Hornberger, C. Anthony Altar, David A. Mrazek, Robert Magner and Leslie R. Harrold and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of the Rheumatic Diseases.

In The Last Decade

Ashwini Shewade

24 papers receiving 254 citations

Peers

Ashwini Shewade
Radu Vasilescu Belgium
Sofia Pazmiño Belgium
S. Kelly United States
Jacqueline R. Chipping United Kingdom
John J. Ko United States
Martin Paton United Kingdom
B. Klemetsdal Norway
Judith Trudeau Canada
Linda Bulone United States
Natasha Alcocer‐Castillejos Mexico
Radu Vasilescu Belgium
Ashwini Shewade
Citations per year, relative to Ashwini Shewade Ashwini Shewade (= 1×) peers Radu Vasilescu

Countries citing papers authored by Ashwini Shewade

Since Specialization
Citations

This map shows the geographic impact of Ashwini Shewade's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ashwini Shewade with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ashwini Shewade more than expected).

Fields of papers citing papers by Ashwini Shewade

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ashwini Shewade. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ashwini Shewade. The network helps show where Ashwini Shewade may publish in the future.

Co-authorship network of co-authors of Ashwini Shewade

This figure shows the co-authorship network connecting the top 25 collaborators of Ashwini Shewade. A scholar is included among the top collaborators of Ashwini Shewade based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ashwini Shewade. Ashwini Shewade is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
McGough, Sarah F., et al.. (2022). An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy. Blood. 140(Supplement 1). 3658–3660. 5 indexed citations
5.
Shewade, Ashwini, Adam J. Olszewski, Andy Surinach, et al.. (2020). Unmet Medical Need Among Elderly Patients with Previously Untreated DLBCL Characterized Using Real-World Data in the United States. Blood. 136(Supplement 1). 6–8. 6 indexed citations
6.
Shewade, Ashwini, Angela Hsieh, Aruna Mani, et al.. (2018). Real-world (RW) characteristics, treatment (tx) patterns, and overall survival (OS) in US patients (pts) with metastatic breast cancer (mBC) and CNS metastases (CNS mets).. Journal of Clinical Oncology. 36(15_suppl). 1037–1037. 5 indexed citations
7.
Shewade, Ashwini, Peter Lambert, Brandon Arnieri, et al.. (2017). Characteristics of advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving molecular diagnostic (MD) testing in U.S. routine clinical practice.. Journal of Clinical Oncology. 35(15_suppl). e20627–e20627. 1 indexed citations
8.
Pappas, Dimitrios A., Ani John, Jeffrey R. Curtis, et al.. (2016). Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry. Rheumatology and Therapy. 3(1). 103–115. 8 indexed citations
9.
Harrold, Leslie R., George Reed, Chitra Karki, et al.. (2016). Risk of Infection Associated With Subsequent Biologic Agent Use After Rituximab: Results From a National Rheumatoid Arthritis Patient Registry. Arthritis Care & Research. 68(12). 1888–1893. 4 indexed citations
10.
11.
Pappas, Dimitrios A., George Reed, Katherine C. Saunders, et al.. (2015). Characteristics Associated with Biologic Monotherapy Use in Biologic-Naive Patients with Rheumatoid Arthritis in a US Registry Population. Rheumatology and Therapy. 2(1). 85–96. 15 indexed citations
12.
Gutierrez, Hialy, Ashwini Shewade, Octavio Gómez‐Dantés, et al.. (2014). Health Care Coverage Decision Making in Low- and Middle-Income Countries: Experiences from 25 Coverage Schemes. Population Health Management. 18(4). 265–271. 8 indexed citations
13.
Altar, C. Anthony, et al.. (2013). Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy. International Review of Psychiatry. 25(5). 509–533. 69 indexed citations
14.
Hornberger, John, Irina Degtiar, Hialy Gutierrez, et al.. (2013). Cost-Effectiveness of Gene-Expression Profiling for Tumor-Site Origin. Value in Health. 16(1). 46–56. 4 indexed citations
15.
Pappas, Dimitrios A., Ani John, Joel M. Kremer, et al.. (2013). OP0005 Effect of Biologic Agents on Lipids and Cardiovascular Risk in Rheumatoid Arthritis Patients. Annals of the Rheumatic Diseases. 72. A49–A49. 2 indexed citations
16.
Harrold, Leslie R., George Reed, Robert Magner, et al.. (2013). FRI0254 Comparative effectiveness of rituximab versus anti-tumor necrosis factor switching for rheumatoid arthritis patients. Annals of the Rheumatic Diseases. 72. A460–A460. 3 indexed citations
17.
18.
Hornberger, John, Carolina Reyes, Ashwini Shewade, et al.. (2011). Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leukemia & lymphoma. 53(2). 225–234. 27 indexed citations
19.
Hornberger, John, Rukmini Rajagopalan, Ashwini Shewade, & Mona Loutfy. (2009). Cost consequences of HIV-associated lipoatrophy. AIDS Care. 21(5). 664–671. 5 indexed citations
20.
Hornberger, John, Rukmini Rajagopalan, Ashwini Shewade, & Mona Loutfy. (2008). Cost consequences of HIV-associated lipoatrophy. Journal of the International AIDS Society. 11(Suppl 1). P318–P318. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Radu Vasilescu Breakdown of academic impact, for papers by Sofia Pazmiño Breakdown of academic impact, for papers by S. Kelly Breakdown of academic impact, for papers by Jacqueline R. Chipping Breakdown of academic impact, for papers by John J. Ko Breakdown of academic impact, for papers by Martin Paton Breakdown of academic impact, for papers by B. Klemetsdal Breakdown of academic impact, for papers by Judith Trudeau Breakdown of academic impact, for papers by Linda Bulone Breakdown of academic impact, for papers by Natasha Alcocer‐Castillejos
Rankless by CCL
2026